home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Corel Medical Series: Cancer
/
Corel Medical Series: Cancer.iso
/
mac
/
Program
/
c29.dxr
/
00058_Field_SRC.c29.C.20.txt
< prev
next >
Wrap
Text File
|
1997-01-28
|
1KB
|
17 lines
Investigational Many investigational protocols are being used in the treatment of ovarian cancer:
• Intra-abdominal administration of single agents such as interferon-alpha , cisplatin , carboplatin , Ara-C ,
bleomycin , mitoxantrone , 5-fluorouracil (5-FU) and etoposide .
• Intra-abdominal melphalan + cytarabine , carboplatin + etoposide (VP-16), monoclonal antibodies to ovarian
carcinoma cells and cisplatin + etoposide with thiosulfate.
• Continuous infusion of intravenous 5-FU .
• Intravenous fludarabine , hexamethylmelamine or cisplatin + 5-FU + etoposide.
• Intravenous carboplatin + ifosfamide . Intravenous Taxol with other drugs.
• Intravenous cisplatin + cyclophosphamide with hyperfractionated (twice daily) abdominal radiotherapy .
• Sodium thiosulfate, which has been shown to protect kidney function as well as lessen the bone marrow
complications of cisplatin chemotherapy .
• High-dose intravenous carboplatin + etoposide with autologous (self-donated) bone marrow transplant.
• High-dosage cyclophosphamide + cisplatin plus chest and abdominal radiation followed by autologous bone
marrow transplant.
• High-dose carboplatin + ifosfamide + mesna with autologous bone marrow transplant.
• Intravenous thiotepa with autologous bone marrow transplant.
• Immunotherapy with interleukin-2 or interleukin-2-activated mononuclear cells.